Sun Pharmaceutical Industries Limited makes specialty pharmaceuticals and active pharmaceutical ingredients (API). Its brands are prescribed in chronic therapy areas, such as cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. Its products introduced during the fiscal year ended March 31, 2007, include Arian, Milmet, Avesta, Sirius, Azura critical care, Solares, Azura life sciences, Sun, Inca, Symbiosis and Synergy. In September 2007, it announced that the United States Food and Drug Administration (FDA) has granted approval for its abbreviated new drug application (ANDA) for Methimazole Tablets USP, five and 10 milligram. In October 2007, the FDA has granted final approval for the Company's ANDA to market its generic version of Novartis Trileptal, oxcarbazepine tablets. In October 2007, it announced that the FDA has granted final marketing approval for its Rivastigmine Tartrate drug.
